

# HUMAN REPRODUCTIVE TECHNOLOGIES: PRODUCTS AND GLOBAL MARKETS



HLC017D  
November 2013

Mary Anne Crandall  
*Project Analyst*

ISBN: 1-56965-644-4

**bcc** | Research  
Market Forecasting

**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481  
866-285-7215, 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
Custom Reports:  
[carol.laverty@bccresearch.com](mailto:carol.laverty@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR STUDY	2
SCOPE OF STUDY	2
METHODOLOGY AND INFORMATION SOURCES	3
INTENDED AUDIENCE	3
ANALYST CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH ONLINE SERVICES	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ BILLIONS)</i>	7
<i>SUMMARY FIGURE TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTION AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 (\$ BILLIONS)</i>	7
CHAPTER 3 INDUSTRY OVERVIEW	9
STRUCTURE AND FUNCTION OF THE REPRODUCTIVE SYSTEM	9
MALE	9
FEMALE	10
Neuroendocrine Regulation	13
Menarche	14
Menstruation Cycle	14
PHASES OF SEXUAL RESPONSES	15
<i>TABLE 1 STRUCTURAL HOMOLOGUES OF THE MALE AND FEMALE REPRODUCTIVE SYSTEMS</i>	15
Male Sexual Response	16
Female Sexual Response	16
NEUROHORMONAL CONTROL OF THE FEMALE AND MALE REPRODUCTIVE SYSTEM	17
Estrogen	18
Progestogens	18
Testosterone	19
EFFECTS OF AGING	19
ISSUES AND TRENDS OF REPRODUCTIVE HEALTH	21
CONTRACEPTIVE INSURANCE	21
OVER-THE-COUNTER BIRTH CONTROL PILLS	21
PREIMPLANTATION GENETIC DIAGNOSIS	22
DESIGNER BABIES	22
NEW USE FOR CONTRACEPTIVES	24
AGING AND INFERTILITY	25
DEATH BY CONTRACEPTIVE PATCH	26
SEXUAL DYSFUNCTION AND CANCER	27
INFERTILITY AND CANCER	28

<b>TOPIC</b>	<b>PAGE NO.</b>
Chemotherapy	28
Radiation	29
Prevention Strategies	30
Procreative Alternatives	30
SIGNALING PATHWAY FOR FERTILITY TREATMENT	31
MARKETING TACTICS	31
MALE BIRTH CONTROL	32
MERCHANDISING TARGETING WOMEN	32
COUNTERFEIT PRODUCTS	32
SURPLUS EMBRYOS AND FETUSES	33
STEM CELL AND OTHER CONTROVERSIAL ISSUES - SELECTED INTERNATIONAL VIEWS	35
CONTROVERSIAL DISPOSAL OF EMBRYOS	39
DEMOGRAPHICS	41
UNITED STATES	41
<i>TABLE 2 U.S. LIVE BIRTH RATES, 1960-2012 (THOUSANDS)</i>	41
<i>FIGURE 1 U.S. LIVE BIRTH RATES, 1960-2012 (THOUSANDS)</i>	42
<i>TABLE 3 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, THROUGH 2030 (THOUSANDS/%)</i>	42
<i>FIGURE 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL POPULATION, 2003-2030 (%)</i>	42
<i>TABLE 4 CHARACTERISTICS OF WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR: 2000 AND 2008 (PER 1,000 WOMEN)</i>	43
<i>TABLE 5 WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR BY AGE AND LABOR FORCE STATUS: 1980-2008</i>	44
<i>TABLE 6 ESTIMATED CONTRACEPTIVE USE BY TYPE BY AGE, ETHNIC GROUP AND MARITAL STATUS (%)</i>	45
EU	45
<i>TABLE 7 BIRTH RATE BY EU COUNTRY AND YEAR, 1960-2011 (PER 1,000 POPULATION (%))</i>	46
ASIA	47
CHAPTER 4 INFERTILITY MARKET	50
INTRODUCTION AND OVERVIEW OF INFERTILITY	50
DEFINITION OF INFERTILITY	50
ETIOLOGY OF INFERTILITY	50
EVALUATION OF FERTILITY	50
Male Factor	51
Artificial Insemination	52
Vaginal and Cervical Factors	55
Immunological Factors	56
Uterine and Tubal Factors	57
Ovarian Factors	58
UNEXPLAINED INFERTILITY	59
MULTIPLE BIRTHS	60
ASIA FACTOR	61
CHAPTER 5 METHODS OF TREATMENT	63
FERTILITY PHARMACEUTICALS	63

<b>TOPIC</b>	<b>PAGE NO.</b>
INTRODUCTION AND TYPES	63
Antagon	64
Bravelle	65
Cetrotide	65
Clomid	65
Crinone and Prometrium	66
Fertinex	67
Follistim	67
Gonal-F	67
Humegon	68
Lupron	68
Novarel	68
Ovidrel	69
Parlodel	69
Pregnyl	69
Profasi	69
Prometrium	69
Repronex	69
Serophene	70
<i>TABLE 8 SELECTED PRESCRIPTION FERTILITY DRUGS</i>	70
MARKET REVENUES AND FORECAST	71
<i>TABLE 9 MARKET SIZE OF GLOBAL INFERTILITY PHARMACEUTICALS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ BILLIONS)</i>	71
FUTURE ADVANCEMENTS IN INFERTILITY PRODUCTS	72
CORIFOLLITROPIN ALFA INJECTION	72
PROGESTERONE VAGINAL RING	72
XM17	72
<i>TABLE 10 INFERTILITY DRUGS IN DEVELOPMENT</i>	72
COMPETITIVE ANALYSIS	72
<i>TABLE 11 GLOBAL INFERTILITY PHARMACEUTICAL MANUFACTURERS' ESTIMATED MARKET SHARE BY REVENUES, 2013 (\$ MILLIONS/%)</i>	73
<i>FIGURE 3 INFERTILITY PHARMACEUTICAL MANUFACTURERS' MARKET SHARE BY REVENUES, 2013 (%)</i>	73
CHAPTER 6 ASSISTIVE REPRODUCTIVE TECHNOLOGIES	75
INTRODUCTION	75
TYPES	75
IVF	75
Ovulation Induction	76
Oocyte Retrieval	76
Intracytoplasmic Sperm Injection (ICSI)	76
Fertilization	77
Embryo Transfer	77
Results of IVF	77
GIFT	78
ZIFT	78
WOMBS FOR RENT	79
OOCYTE DONATION	80

<b>TOPIC</b>	<b>PAGE NO.</b>
FROZEN EMBRYOS	81
UNITED STATES FERTILITY CLINICS	82
<i>TABLE 12 NATIONAL SUMMARY OF ASSISTIVE REPRODUCTIVE THERAPIES, 2011 (U.S.)</i>	82
<i>TABLE 13 NATIONAL ASSISTIVE REPRODUCTIVE THERAPIES CYCLE PROFILE, 2011 (%)</i>	82
<i>TABLE 14 PREGNANCY SUCCESS RATES, 2011</i>	83
INTERNATIONAL FERTILITY CLINICS	84
<i>TABLE 15 NUMBER OF IVF CENTERS BY SELECT COUNTRIES</i>	84
MARKET REVENUES AND FORECAST	85
<i>TABLE 16 MARKET SIZE OF GLOBAL ASSISTIVE REPRODUCTIVE TECHNOLOGIES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ MILLIONS)</i>	85
FUTURE TRENDS IN ASSISTIVE REPRODUCTIVE TECHNOLOGY	85
COMPETITIVE ANALYSIS	87
<i>TABLE 17 GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE PRODUCTS' ESTIMATED MARKET SHARE BY ESTIMATED REVENUES, 2013 (\$ MILLIONS/%)</i>	87
<i>FIGURE 4 GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE MARKET SHARES BY REVENUES, 2013 (%)</i>	87
CHAPTER 7 FERTILITY DIAGNOSTICS	90
INTRODUCTION	90
TYPES	90
Urine Studies	90
Pregnancy Testing	90
Ovulation Testing	91
Sperm Testing	92
Hormone Studies	93
Blood Studies	93
MARKET REVENUES AND FORECAST	94
<i>TABLE 18 MARKET SIZE OF GLOBAL FERTILITY DIAGNOSTICS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ MILLIONS)</i>	94
COMPETITIVE ANALYSIS	94
<i>TABLE 19 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (\$ MILLIONS/%)</i>	94
<i>FIGURE 5 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)</i>	95
FUTURE ADVANCEMENTS IN DIAGNOSTIC FERTILITY TREATMENT	95
TOTAL INFERTILITY MARKET REVENUES AND FORECAST	96
<i>TABLE 20 MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ MILLIONS)</i>	96
<i>FIGURE 6 MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 (\$ MILLIONS)</i>	96
CHAPTER 8 CONTRACEPTION MARKET	98
INTRODUCTION AND OVERVIEW OF CONTRACEPTION	98
<i>TABLE 21 CONTRACEPTIVE STATUS AND USE RATES, U.S. WOMEN AGED 15-44., 2011 (THOUSANDS)</i>	100
<i>TABLE 22 CONTRACEPTIVE USE RATES BY REGIONS, 2011 (PERCENT)</i>	100
PHARMACEUTICALS	101
Types	101

<b>TOPIC</b>	<b>PAGE NO.</b>
Oral Contraceptives	101
<i>TABLE 23 MOST COMMONLY USED ORAL AND TRANSDERMAL CONTRACEPTIVES, 2013</i>	103
Alesse	105
Beyaz	105
Brevicon and Norinyl	105
Desogen	105
Estrostep	105
Levlen ED	106
Levora	106
Lo -Loestrin	106
Lo/Ovral	106
Low-Ogestrel	106
Lybrel	106
Microgestin	107
Mircette	107
Natazia	107
Necon	107
Nordette	107
Nor-QD	107
Ortho Evra	108
Ortho Micronor	108
Ortho Tri-Cyclen	108
OrthoCept	108
Ovcon 35	109
Ovral	109
Quartette	109
Safyral	109
Seasonale	109
Tri-Levlen	110
Tri-Norinyl	110
Triphasil	110
Trivora	110
Yasmin 28	110
Zovia	111
Zoely	111
<i>TABLE 24 ESTROGEN AND PROGESTIN HORMONE DOSES IN COMBINED BIRTH CONTROL PILLS</i>	111
<i>TABLE 25 POTENCY OF DIFFERENT ORAL CONTRACEPTIVE PROGESTINS</i>	113
<i>TABLE 26 CURRENT PILL PROBLEMS AND CHOICE OF PILL TO SWITCH TO</i>	113
OTHER DRUG REGIMENS FOR CONTRACEPTION	114
Depo-Provera	114
Plan B One Step	114
Mifeprex	115
MARKET REVENUES AND FORECAST	115
<i>TABLE 27 MARKET SIZE OF GLOBAL CONTRACEPTIVE PHARMACEUTICALS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ BILLIONS)</i>	116
COMPETITIVE ANALYSIS	116

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 28 GLOBAL CONTRACEPTIVE PHARMACEUTICAL MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (\$ MILLIONS/%)</i>	116
<i>FIGURE 7 GLOBAL CONTRACEPTIVE PHARMACEUTICALS MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)</i>	116
PRESCRIPTION DEVICES	117
INTRODUCTION AND TYPES	117
Intrauterine Devices	118
NuvaRing	118
Implanon	119
<i>TABLE 29 SELECTED CONTRACEPTIVE DEVICE TREATMENTS 2013</i>	119
MARKET REVENUES AND FORECAST	119
<i>TABLE 30 MARKET SIZE OF GLOBAL CONTRACEPTIVE DEVICES AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ BILLIONS)</i>	120
COMPETITIVE ANALYSIS	120
<i>TABLE 31 GLOBAL CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (\$ MILLIONS/%)</i>	120
<i>FIGURE 8 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)</i>	120
FUTURE ADVANCEMENTS IN CONTRACEPTION	121
<i>TABLE 32 CONTRACEPTIVES IN DEVELOPMENT</i>	121
AG-200-15	122
ARC	122
C31G (SAVVY)	122
FC PATCH	122
LECETTE	122
AG890	123
USHERCELL	123
LEVOSERT IUD	123
TOTAL MARKET REVENUES AND FORECAST	123
<i>TABLE 33 MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ MILLIONS)</i>	123
<i>FIGURE 9 MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 (\$ MILLIONS)</i>	124
<b>CHAPTER 9 SEXUAL DYSFUNCTION MARKET</b>	<b>126</b>
INTRODUCTION AND OVERVIEW	126
TYPES OF SEXUAL DYSFUNCTION	126
CAUSES OF SEXUAL DYSFUNCTION	127
DEMOGRAPHICS OF SEXUAL DYSFUNCTION	127
PHARMACEUTICALS	128
Introduction and Types	128
Viagra	128
Cialis	128
Levitra	128
Staxyn	129
Stendra/Spendra	129
Yohimbine	129
Caverject	129
MUSE	129

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 34 SELECTED SEXUAL DYSFUNCTION PHARMACEUTICAL TREATMENTS</i>	130
MARKET REVENUES AND FORECAST	130
<i>TABLE 35 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ BILLIONS)</i>	131
COMPETITIVE ANALYSIS	131
<i>TABLE 36 GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (\$ MILLIONS/%)</i>	131
<i>FIGURE 10 GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)</i>	131
DEVICES	132
Introduction and Types	132
SomaTherapy-ED SOMAerect Stf	132
Viberec	133
Erectaid Classic System	133
AMS Inflatable Penile Implant	134
Coloplast Titan OTR	134
<i>TABLE 37 SELECTED SEXUAL DYSFUNCTION DEVICE TREATMENTS</i>	134
MARKET REVENUES AND FORECAST	134
<i>TABLE 38 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION DEVICES AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ MILLIONS)</i>	135
COMPETITIVE ANALYSIS	135
<i>TABLE 39 GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (\$ MILLIONS/%)</i>	135
<i>FIGURE 11 GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)</i>	135
FUTURE ADVANCEMENTS IN SEXUAL DYSFUNCTION	136
<i>TABLE 40 SEXUAL DYSFUNCTION DRUGS IN DEVELOPMENT</i>	136
Flibanserin	137
Femprox	137
LibiGel	137
Lybrido and Lybridos	137
Tefina	138
Topiglan	138
Zoraxel	138
Zydena (udenafil)	138
TOTAL MARKET REVENUES AND FORECAST	138
<i>TABLE 41 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ MILLIONS)</i>	139
<i>FIGURE 12 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 (\$ MILLIONS)</i>	139
CHAPTER 10 PATENTS	141
PATENT ANALYSIS BY MANUFACTURER	141
<i>TABLE 42 SELECTED MANUFACTURER PATENTS FOR REPRODUCTIVE PRODUCTS AND RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT</i>	141
PATENTS BY APPLICATION	141
INFERTILITY TREATMENTS	141
CONTRACEPTION	142
SEXUAL DYSFUNCTION	142



<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 11 LEADING MARKET MANUFACTURERS	144
<i>TABLE 43 PATENT ANALYSIS BY SELECTED LEADING REPRODUCTIVE TREATMENT MANUFACTURERS, 1976-PRESENT</i>	144
CHAPTER 12 TOTAL MARKET	147
<i>TABLE 44 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ BILLIONS)</i>	147
TOTAL GLOBAL MARKET FOR REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY REGION	147
<i>TABLE 45 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2013 (\$ MILLIONS/%)</i>	148
<i>FIGURE 13 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET SHARE BY SELECTED GEOGRAPHIC REGIONS, 2013 (%)</i>	148
<i>TABLE 46 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2018 (\$ MILLIONS/%)</i>	149
<i>FIGURE 14 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET SHARE BY SELECTED GEOGRAPHIC REGIONS, 2018 (%)</i>	149
TOTAL MARKET SIZE BY CATEGORY	149
<i>TABLE 47 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ MILLIONS)</i>	150
<i>FIGURE 15 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 (\$ MILLIONS)</i>	150
<i>TABLE 48 TOTAL ESTIMATED GLOBAL REVENUES, MARKET SHARE AND NUMBER OF MANUFACTURERS OF REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY MARKET SEGMENT, 2013 (\$ MILLIONS/%)</i>	151
<i>FIGURE 16 NUMBER OF SELECTED MANUFACTURERS BY MARKET SEGMENT, 2013</i>	151
<i>FIGURE 17 MARKET SHARE BY MARKET SEGMENT, 2013 (%)</i>	151
INDUSTRY PARTICIPANTS BY CATEGORY	152
<i>TABLE 49 REPRODUCTIVE INDUSTRY PARTICIPANTS BY PRODUCT CATEGORY</i>	152
TOTAL MARKET SIZE BY PRODUCT TYPE	154
<i>TABLE 50 TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ MILLIONS)</i>	154
<i>FIGURE 18 TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 (\$ MILLIONS)</i>	155
CHAPTER 13 PARTICIPATING COMPANIES	157
COMPANY PROFILES	157
ACTAVIS, INC	157
BAYER AG	157
BRISTOL-MYERS SQUIBB CO.	159
CHURCH & DWIGHT COMPANY INC.	159
COOPERSURGICAL INC.	159
ELI LILLY & CO.	160
EMD SERONO, INC	160
FERRING PHARMACEUTICALS	161
GLAXOSMITHKLINE PLC	161

<b>TOPIC</b>	<b>PAGE NO.</b>
JANSSEN PHARMACEUTICAL	162
MERCK INC.	162
NOVARTIS INTERNATIONAL AG	163
PFIZER INC.	163
PRINCETON BIOMEDITECH CORP.	164
QUIDEL CORP	164
VIVUS INC.	165
CHAPTER 14 APPENDIX A	167
SELECTED LIST OF U.S. FERTILITY CLINICS	167
ALABAMA	167
ARIZONA	167
CALIFORNIA	168
COLORADO	169
CONNECTICUT	170
DISTRICT OF COLUMBIA	170
FLORIDA	170
GEORGIA	171
IDAHO	171
ILLINOIS	171
INDIANA	172
KANSAS	173
MAINE	173
MARYLAND	173
MASSACHUSETTS	173
MICHIGAN	174
MINNESOTA	174
MONTANA	174
NEVADA	174
NEW HAMPSHIRE	175
NEW JERSEY	175
NEW YORK	176
NORTH CAROLINA	176
OREGON	176
RHODE ISLAND	177
SOUTH CAROLINA	177
SOUTH DAKOTA	177
TEXAS	177
UTAH	178
VIRGINIA	178
WASHINGTON	178
SELECTED LIST OF FERTILITY CLINICS IN OTHER REGIONS	179
ASIAN FERTILITY CLINICS	179
AUSTRIA	180
Innsbruck	180
Vienna	180
SWITZERLAND	181

<b>TOPIC</b>	<b>PAGE NO.</b>
Basel	181
Geneva	181
Zurich	182
GERMANY	182
FRANCE	183
Paris	183
ITALY	183
Naples	183
Rome	184
GREAT BRITAIN	184
London	184
CHAPTER 15 APPENDIX B: LIST OF COMPANIES	187
<i>TABLE 51 LIST OF COMPANIES</i>	187

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ BILLIONS)	7
TABLE 1 STRUCTURAL HOMOLOGUES OF THE MALE AND FEMALE REPRODUCTIVE SYSTEMS	15
TABLE 2 U.S. LIVE BIRTH RATES, 1960-2012 (THOUSANDS)	41
TABLE 3 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, THROUGH 2030 (THOUSANDS/%)	42
TABLE 4 CHARACTERISTICS OF WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR: 2000 AND 2008 (PER 1,000 WOMEN)	43
TABLE 5 WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR BY AGE AND LABOR FORCE STATUS: 1980-2008	44
TABLE 6 ESTIMATED CONTRACEPTIVE USE BY TYPE BY AGE, ETHNIC GROUP AND MARITAL STATUS (%)	45
TABLE 7 BIRTH RATE BY EU COUNTRY AND YEAR, 1960-2011 (PER 1,000 POPULATION (%))	46
TABLE 8 SELECTED PRESCRIPTION FERTILITY DRUGS	70
TABLE 9 MARKET SIZE OF GLOBAL INFERTILITY PHARMACEUTICALS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ BILLIONS)	71
TABLE 10 INFERTILITY DRUGS IN DEVELOPMENT	72
TABLE 11 GLOBAL INFERTILITY PHARMACEUTICAL MANUFACTURERS' ESTIMATED MARKET SHARE BY REVENUES, 2013 (\$ MILLIONS/%)	73
TABLE 12 NATIONAL SUMMARY OF ASSISTIVE REPRODUCTIVE THERAPIES, 2011 (U.S.)	82
TABLE 13 NATIONAL ASSISTIVE REPRODUCTIVE THERAPIES CYCLE PROFILE, 2011 (%)	82
TABLE 14 PREGNANCY SUCCESS RATES, 2011	83
TABLE 15 NUMBER OF IVF CENTERS BY SELECT COUNTRIES	84
TABLE 16 MARKET SIZE OF GLOBAL ASSISTIVE REPRODUCTIVE TECHNOLOGIES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ MILLIONS)	85
TABLE 17 GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE PRODUCTS' ESTIMATED MARKET SHARE BY ESTIMATED REVENUES, 2013 (\$ MILLIONS/%)	87
TABLE 18 MARKET SIZE OF GLOBAL FERTILITY DIAGNOSTICS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ MILLIONS)	94
TABLE 19 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (\$ MILLIONS/%)	94
TABLE 20 MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ MILLIONS)	96
TABLE 21 CONTRACEPTIVE STATUS AND USE RATES, U.S. WOMEN AGED 15-44., 2011 (THOUSANDS)	100
TABLE 22 CONTRACEPTIVE USE RATES BY REGIONS, 2011 (PERCENT)	100
TABLE 23 MOST COMMONLY USED ORAL AND TRANSDERMAL CONTRACEPTIVES, 2013	103
TABLE 24 ESTROGEN AND PROGESTIN HORMONE DOSES IN COMBINED BIRTH CONTROL PILLS	111
TABLE 25 POTENCY OF DIFFERENT ORAL CONTRACEPTIVE PROGESTINS	113
TABLE 26 CURRENT PILL PROBLEMS AND CHOICE OF PILL TO SWITCH TO	113
TABLE 27 MARKET SIZE OF GLOBAL CONTRACEPTIVE PHARMACEUTICALS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ BILLIONS)	116
TABLE 28 GLOBAL CONTRACEPTIVE PHARMACEUTICAL MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (\$ MILLIONS/%)	116

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 29 SELECTED CONTRACEPTIVE DEVICE TREATMENTS 2013	119
TABLE 30 MARKET SIZE OF GLOBAL CONTRACEPTIVE DEVICES AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ BILLIONS)	120
TABLE 31 GLOBAL CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (\$ MILLIONS/%)	120
TABLE 32 CONTRACEPTIVES IN DEVELOPMENT	121
TABLE 33 MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ MILLIONS)	123
TABLE 34 SELECTED SEXUAL DYSFUNCTION PHARMACEUTICAL TREATMENTS	130
TABLE 35 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ BILLIONS)	131
TABLE 36 GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (\$ MILLIONS/%)	131
TABLE 37 SELECTED SEXUAL DYSFUNCTION DEVICE TREATMENTS	134
TABLE 38 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION DEVICES AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ MILLIONS)	135
TABLE 39 GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (\$ MILLIONS/%)	135
TABLE 40 SEXUAL DYSFUNCTION DRUGS IN DEVELOPMENT	136
TABLE 41 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ MILLIONS)	139
TABLE 42 SELECTED MANUFACTURER PATENTS FOR REPRODUCTIVE PRODUCTS AND RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT	141
TABLE 43 PATENT ANALYSIS BY SELECTED LEADING REPRODUCTIVE TREATMENT MANUFACTURERS, 1976-PRESENT	144
TABLE 44 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ BILLIONS)	147
TABLE 45 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2013 (\$ MILLIONS/%)	148
TABLE 46 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2018 (\$ MILLIONS/%)	149
TABLE 47 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ MILLIONS)	150
TABLE 48 TOTAL ESTIMATED GLOBAL REVENUES, MARKET SHARE AND NUMBER OF MANUFACTURERS OF REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY MARKET SEGMENT, 2013 (\$ MILLIONS/%)	151
TABLE 49 REPRODUCTIVE INDUSTRY PARTICIPANTS BY PRODUCT CATEGORY	152
TABLE 50 TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 (\$ MILLIONS)	154
TABLE 51 LIST OF COMPANIES	187

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTION AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 (\$ BILLIONS)	7
FIGURE 1 U.S. LIVE BIRTH RATES, 1960-2012 (THOUSANDS)	42
FIGURE 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL POPULATION, 2003-2030 (%)	42
FIGURE 3 INFERTILITY PHARMACEUTICAL MANUFACTURERS' MARKET SHARE BY REVENUES, 2013 (%)	73
FIGURE 4 GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE MARKET SHARES BY REVENUES, 2013 (%)	87
FIGURE 5 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)	95
FIGURE 6 MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 (\$ MILLIONS)	96
FIGURE 7 GLOBAL CONTRACEPTIVE PHARMACEUTICALS MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)	116
FIGURE 8 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)	120
FIGURE 9 MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 (\$ MILLIONS)	124
FIGURE 10 GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)	131
FIGURE 11 GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)	135
FIGURE 12 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 (\$ MILLIONS)	139
FIGURE 13 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET SHARE BY SELECTED GEOGRAPHIC REGIONS, 2013 (%)	148
FIGURE 14 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET SHARE BY SELECTED GEOGRAPHIC REGIONS, 2018 (%)	149
FIGURE 15 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 (\$ MILLIONS)	150
FIGURE 16 NUMBER OF SELECTED MANUFACTURERS BY MARKET SEGMENT, 2013	151
FIGURE 17 MARKET SHARE BY MARKET SEGMENT, 2013 (%)	151
FIGURE 18 TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 (\$ MILLIONS)	155